{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:10Z","timestamp":1793091250117,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea","award":["HI14C2664\/HI17C0175"],"award-info":[{"award-number":["HI14C2664\/HI17C0175"]}]},{"name":"Ministry of Food and Drug Administration","award":["16172MFDS261"],"award-info":[{"award-number":["16172MFDS261"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vaccine.2019.02.048","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T14:37:43Z","timestamp":1551364663000},"page":"2131-2141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice"],"prefix":"10.1016","volume":"37","author":[{"given":"Seo Ri","family":"Wui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji In","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Thi Thu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hark Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Ae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Je","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Gyeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Gyong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.02.048_b0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0010","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol."},{"key":"10.1016\/j.vaccine.2019.02.048_b0015","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/JVI.03445-13","article-title":"Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia","volume":"88","author":"Steain","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/421277","article-title":"Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus","volume":"190","author":"Vossen","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0025","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/infdis\/jiy382","article-title":"Herpes zoster vaccines","volume":"218","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/infdis\/166.2.253","article-title":"Immune response of elderly individuals to a live attenuated varicella vaccine","volume":"166","author":"Levin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0035","first-page":"729","article-title":"Centers for Disease C, Prevention. Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.02.048_b0040","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.048_b0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0050","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2019.02.048_b0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.048_b0060","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.048_b0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.048_b0070","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/17425247.2016.1151871","article-title":"Liposomal adjuvants for human vaccines","volume":"13","author":"Alving","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2019.02.048_b0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0080","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1016\/j.vaccine.2014.07.081","article-title":"Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.048_b0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Henriksen-Lacey","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.02.048_b0090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2567.2007.02560.x","article-title":"The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes","volume":"121","author":"Korsholm","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2019.02.048_b0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jconrel.2014.06.027","article-title":"Designing and building the next generation of improved vaccine adjuvants","volume":"190","author":"Brito","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.02.048_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010007","article-title":"Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators","volume":"8","author":"Tandrup Schmidt","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2019.02.048_b0105","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1039\/c1nr10166h","article-title":"The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses","volume":"3","author":"Ma","year":"2011","journal-title":"Nanoscale"},{"key":"10.1016\/j.vaccine.2019.02.048_b0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09687860600790537","article-title":"Immunostimulation of dendritic cells by cationic liposomes","volume":"23","author":"Vangasseri","year":"2006","journal-title":"Mol Membr Biol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0115","doi-asserted-by":"crossref","DOI":"10.1007\/112_2018_9","article-title":"Potential of cationic liposomes as adjuvants\/delivery systems for Tuberculosis subunit vaccines","author":"Khademi","year":"2018","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.02.048_b0125","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.048_b0130","article-title":"Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide","volume":"9","author":"Han","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.02.048_b0135","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1016\/j.vaccine.2012.04.079","article-title":"Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix in mice","volume":"30","author":"Han","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.048_b0140","doi-asserted-by":"crossref","first-page":"3713656","DOI":"10.1155\/2016\/3713656","article-title":"A de-O-acylated lipooligosaccharide-based adjuvant system promotes antibody and Th1-type immune responses to H1N1 pandemic influenza vaccine in mice","volume":"2016","author":"Ryu","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2019.02.048_b0145","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.4014\/jmb.1706.06009","article-title":"Increased immunogenicity and protective efficacy of a P. aeruginosa vaccine in mice using an alum and de-O-acylated lipooligosaccharide adjuvant system","volume":"27","author":"Ryu","year":"2017","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0150","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.intimp.2011.03.020","article-title":"A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice","volume":"11","author":"Wui","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12272-013-0034-5","article-title":"Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine","volume":"36","author":"Wui","year":"2013","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.vaccine.2019.02.048_b0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12272-017-0985-z","article-title":"Comparison of the adjuvanticity of two adjuvant formulations containing de-O-acylated lipooligosaccharide on Japanese encephalitis vaccine in mice","volume":"41","author":"Ko","year":"2018","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.vaccine.2019.02.048_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00423-3","article-title":"Lyophilization and development of solid protein pharmaceuticals","volume":"203","author":"Wang","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2019.02.048_b0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.02.048_b0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.chemphyslip.2013.10.011","article-title":"Novel methods for liposome preparation","volume":"177","author":"Patil","year":"2014","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.vaccine.2019.02.048_b0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6591-5_2","article-title":"Thin-film hydration followed by extrusion method for liposome preparation","volume":"1522","author":"Zhang","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0185","first-page":"711","article-title":"Liposomes: an overview of manufacturing techniques","volume":"10","author":"Mozafari","year":"2005","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.vaccine.2019.02.048_b0190","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1016\/j.vaccine.2006.04.048","article-title":"A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy","volume":"24","author":"Cho","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.048_b0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/abio.1998.2961","article-title":"Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation","volume":"267","author":"Lee","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2019.02.048_b0200","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.048_b0205","doi-asserted-by":"crossref","first-page":"20577","DOI":"10.1038\/srep20577","article-title":"Serological evaluation of immunity to the varicella-zoster virus based on a novel competitive enzyme-linked immunosorbent assay","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.02.048_b0210","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.4049\/jimmunol.161.8.4000","article-title":"Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen","volume":"161","author":"Brewer","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.exppara.2012.09.001","article-title":"The role of liposome size on the type of immune response induced in BALB\/c mice against leishmaniasis: rgp63 as a model antigen","volume":"132","author":"Badiee","year":"2012","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.05.019","article-title":"The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production","volume":"154","author":"Henriksen-Lacey","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.02.048_b0225","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.173.10.6143","article-title":"Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles","volume":"173","author":"Brewer","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0230","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.molimm.2007.04.009","article-title":"Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines","volume":"44","author":"Yan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0235","first-page":"663","article-title":"Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21","volume":"7","author":"Welsby","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.02.048_b0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2019.02.048_b0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0250","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0255","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0260","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.048_b0265","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster Vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus","volume":"212","author":"Laing","year":"2015","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T01:16:44Z","timestamp":1694654204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19302555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":53,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0264410X19302555"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}